Receptor for advanced glycation end products in bacterial infection: Is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?

Current Opinion in Infectious Diseases

Volumn 25, Issue 3, 2012, Pages 304-311

  Christaki, Eirini ^a,b   Lazaridis, Nikolaos ^b   Opal, Steven M ^a  

^a BROWN UNIVERSITY   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

immunomodulation; receptor for advanced glycation end products; sepsis; septic shock

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIBODY; CYTOKINE; GLUTAMINE; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN S 100; SMALL INTERFERING RNA; SPERMINE;

APOPTOSIS; BACTERIAL INFECTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG TARGETING; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; KNOCKOUT GENE; NONHUMAN; REVIEW; SEPSIS;

FEMALE; HUMANS; INFLAMMATION; MALE; RECEPTORS, IMMUNOLOGIC; RNA, SMALL INTERFERING; SEPSIS; SIGNAL TRANSDUCTION;

EID: 84861095798     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283519b82     Document Type: Review

References (47)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
2. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83:876-886. This is an important review of RAGE and its role in inflammation and infection.
3. Valente T, Gella A, Fernandez-Busquets X, et al. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37:67-76.
4. Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005; 64:92-100.
5. Ramasamy R, Yan SF, Schmidt AM. The RAGE axis and endothelial dysfunction: Maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovascr Med 2005; 15:237-243.
6. Schmidt AM, Hofmann M, Taguchi A, et al. RAGE: A multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost 2000; 26:485-493.
7. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267:14998-15004.
8. Chavakis T, Bierhaus A, Al-Fakhri N, et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198:1507-1515.
9. Xie J, Reverdatto S, Frolov A, et al. Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE). J Biol Chem 2008; 283:27255-27269.
10. Jin Q, Chen H, Luo A, et al. S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One 2011; 6:e19375.
11. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418:191-195.
12. Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901.
13. Xie J, Burz DS, He W, et al. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2007; 282:4218-4231.
14. Ostendorp T, Leclerc E, Galichet A, et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 2007; 26:3868-3878.
15. Leclerc E, FritzG, WeibelM, et al. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 2007; 282: 31317-31331.
16. Xue J, Rai V, Singer D, et al. Advanced glycation end product recognition by the receptor for AGEs. Structure 2011; 19:722-732.
17. Yamamoto Y, Harashima A, Saito H, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011; 186:3248-3257. Using surface plasmon resonance, these investigators convincingly demonstrate that LPS binds directly to RAGE. This finding challenges the longstanding notion that RAGE does not recognize PAMPs and is only a PRR of host-derived DAMPs.
18. Sakaguchi M, Murata H, Yamamoto K, et al. TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS One 2011; 6:e23132.
19. Raucci A, Cugusi S, Antonelli A, et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008; 22:3716-3727.
20. Santilli F, Vazzana N, Bucciarelli LG, Davi G. Soluble forms of RAGE in human diseases: Clinical and therapeutical implications. Curr Med Chem 2009; 16:940-952.
21. Kalea AZ, Reiniger N, Yang H, et al. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J 2009; 23:1766-1774.
22. Jabaudon M, Futier E, Roszyk L, et al. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 2011; 39:480-488.
23. Nakamura T, Sato E, Fujiwara N, et al. Suppression of high-mobility group box-1 and receptor for advanced glycation end-product axis by polymyxin B-immobilized fiber hemoperfusion in septic shock patients. J Crit Care 2011; 26:546-549.
24. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury. Thorax 2008; 63:1083-1089.
25. Bopp C, Hofer S, Weitz J, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008; 147:79-83.
26. Yamakawa N, Uchida T, Matthay MA, Makita K. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol 2011; 300:L516-525.
27. van Zoelen MA, Schouten M, de Vos AF, et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182:4349-4356.
28. Lutterloh EC, Opal SM, Pittman DD, et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11:R122.
29. Christaki E, Opal SM, Keith JC Jr, et al. A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumonia. Shock 2011; 35:492-498.
30. van Zoelen MA, Schmidt AM, Florquin S, et al. Receptor for advanced glycation end products facilitates host defense during Escherichia coliinduced abdominal sepsis in mice. J Infect Dis 2009; 200:765-773.
31. Tadie JM, Bae HB, Banerjee S, et al. Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing. Am J Physiol Cell Physiol 2012; 302:C249-C256.
32. Huang W, Liu Y, Li L, et al. HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation 2011. [Epub ahead of print]
33. Ramsgaard L, Englert JM, Manni ML, et al. Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. PLoS One 2011; 6:e20132.
34. van Zoelen MA, Achouiti A, Schmidt AM, et al. Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med 2010; 38:1414-1422.
35. Susa Y, Masuda Y, Imaizumi H, Namiki A. Neutralization of receptor for advanced glycation end-products and high mobility group box-1 attenuates septic diaphragm dysfunction in rats with peritonitis. Crit Care Med 2009; 37:2619-2624.
36. van Zoelen MA, van der Sluijs KF, Achouiti A, et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009; 391:265-273.
37. Wolfson RK, Chiang ET, Garcia JG. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 2011; 81:189-197.
38. Hu YM, Pai MH, Yeh CL, et al. Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol 2012; 302:F150-F158.
39. Kwon WY, Suh GJ, Kim KS, et al. Glutamine attenuates acute lung injury by inhibition of high mobility group box protein-1 expression during sepsis. Br J Nutr 2010; 103:890-898.
40. Zhu S, Ashok M, Li J, et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009; 15 (7-8):275-282.
41. Buckley ST, Ehrhardt C. The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010; 2010:917108.
42. Vugmeyster Y, DeFranco D, Pittman DD, Xu X. Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice. mAbs 2010; 2:571-575.
43. Bopp C, Bierhaus A, Hofer S, et al. Bench-to-bedside review: The inflammation- perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008; 12:201.
44. He M, Kubo H, Morimoto K, et al. Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. EMBO Rep 2011; 12:358-364.
45. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009; 31:280-284.
46. Takahashi G, Hoshikawa K, Matsumoto N, et al. Changes in serum S100A12 and sRAGE associated with improvement of the PaO(2)/FiO(2) ratio following PMX-DHP therapy for postoperative septic shock. Eur Surg Res 2011; 47:135-140.
47. Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 2012; 359 (1-2):73-81